INmune Bio
INMB · Nasdaq · United States
Share price · INMB
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when INMB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026+7.3%
Nothing announced by INMB that day or the session before.
- 30 Oct 2026-9.4%
- 16 Sep 2026-9.3%
Nothing announced by INMB that day or the session before.
- 10 Jul 2026+8.4%
Nothing announced by INMB that day or the session before.
- 29 Jun 2026+14.1%
Nothing announced by INMB that day or the session before.
- 18 Jun 2026+11.5%
- 14 May 2026+15.1%
- 11 Mar 2026+10.9%
Nothing announced by INMB that day or the session before.
- 23 Dec 2025-9.6%
- 9 Dec 2025+6.4%
Share of unusual movement by asset
For each asset, the share of INMB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Pegipanerminevents and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 2% |
| Other company news (earnings, financing, releases naming no asset) | — | 41% |
| Sessions with no dated event | — | 57% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Soluble TNF (selective)Biologic (subtype unspecified) | Alzheimer's Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | — | $16M | $4.7M-$3.4M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | — | $18M | $1.3M-$3.2M operating cash flow | report ↗ |
| 2026-Q1 | — | $3.6M | $21M | $5.4M-$3.4M operating cash flow | report ↗ |
| 2025-Q3 | — | $4.9M | $28M | $6.5M-$5.4M operating cash flow | report ↗ |
| 2025-Q2 | — | $5.8M | $33M | $24M-$7.4M operating cash flow | report ↗ |
| 2025-Q1 | $0.1M | $7.6M | $19M | $9.7M-$6.8M operating cash flow | report ↗ |
| 2024-Q3 | — | $10M | $34M | $12M-$7.0M operating cash flow | report ↗ |
| 2024-Q2 | — | $7.0M | $31M | $9.8M-$7.9M operating cash flow | report ↗ |
| 2024-Q1 | <$0.1M | $8.7M | $26M | $11M-$7.5M operating cash flow | report ↗ |
| 2023-Q3 | <$0.1M | $6.0M | $42M | $8.6M-$4.3M operating cash flow | report ↗ |
| 2023-Q2 | $0.1M | $4.2M | $48M | $6.5M-$3.2M operating cash flow | report ↗ |
| 2023-Q1 | <$0.1M | $4.1M | $51M | $6.5M-$1.1M operating cash flow | report ↗ |
| 2022-Q3 | $0.1M | $5.2M | $57M | $7.7M-$3.4M operating cash flow | report ↗ |
| 2022-Q2 | <$0.1M | $4.2M | $61M | $6.8M-$4.8M operating cash flow | report ↗ |
| 2022-Q1 | $0.2M | $4.3M | $67M | $6.9M-$8.9M operating cash flow | report ↗ |
| 2021-Q3 | <$0.1M | $6.5M | — | $9.5M-$7.9M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0.1M | $21M | $25M | $11M-$23M operating cash flow | report ↗ |
For fiscal year 2025, INmune Bio reported revenue of $0.05M, up 400.0% YoY, with R&D spend of $20.66M, down 37.7% YoY. Cash and equivalents stood at $24.75M, and the company reported a net loss of $45.93M, with reported quarterly net burn of $45.93M.
The company did not provide financial guidance but disclosed regulatory and clinical milestones. CORDStrom regulatory submissions are planned for a UK MAA in July 2026, EU MAA in September 2026, and FDA BLA in December 2026. XPro’s Phase II trial missed its primary and key secondary endpoints, though a prespecified enriched subgroup showed favorable signals, and an end-of-Phase 2 FDA meeting in January 2026 confirmed alignment on a proposed integrated Phase 2b/3 strategy, which the company intends to pursue through a strategic partnership rather than independently. INKmune’s Phase I/II trial in metastatic castrate-resistant prostate cancer completed enrollment in Q4 2025, with top-line data expected about six months later, but the company does not intend to advance INKmune further at this time due to capital constraints.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-15 | Clark Ronnie Duane · director | Award / grant (derivative) | 100,000 | — | — | Form 4 |
| 2026-09-15 | SAPIRSTEIN JAMES · director | Award / grant (derivative) | 100,000 | — | — | Form 4 |
| 2026-07-02 | Moss David J · director, Chief Executive Officer | Option exercise | 9,014 | $1.40 | $13K | Form 4 |
| 2026-07-02 | Lowdell Mark William · Chief Scientific Officer | Option exercise | 7,211 | $1.40 | $10K | Form 4 |
| 2026-07-02 | Juda Scott · director | Option exercise | 14,801 | $1.40 | $21K | Form 4 |
| 2026-07-02 | Moss David J · director, Chief Executive Officer | Option exercise (derivative) | 9,014 | $0.13 | $1K | Form 4 |
| 2026-07-02 | Lowdell Mark William · Chief Scientific Officer | Option exercise (derivative) | 7,211 | $0.13 | $901 | Form 4 |
| 2026-07-02 | Juda Scott · director | Option exercise (derivative) | 14,801 | $0.13 | $2K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 81 reporting institutions held 5.4M shares ($6.1M, 17.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 1,194,112 | $1.3M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 687,015 | $776K |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 494,969 | $559K |
| 4 | STATE STREET CORP | 290,879 | $329K |
| 5 | AQR CAPITAL MANAGEMENT LLC | 270,317 | $305K |
| 6 | UBS Group AG | 253,340 | $286K |
| 7 | GOLDMAN SACHS GROUP INC | 231,586 | $262K |
| 8 | RAYMOND JAMES FINANCIAL INC | 203,245 | $230K |
| 9 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 194,391 | $220K |
| 10 | NORTHERN TRUST CORP | 184,225 | $208K |
| 11 | Dauntless Investment Group, LLC | 183,476 | $207K |
| 12 | VANGUARD PORTFOLIO MANAGEMENT LLC | 129,218 | $146K |
| 13 | VANGUARD FIDUCIARY TRUST CO | 123,184 | $139K |
| 14 | Westside Investment Management, Inc. | 108,300 | $122K |
| 15 | Bank of New York Mellon Corp | 53,628 | $61K |